GLP-1 agonists reduce risk of Stroke and provide neuroprotection to diabetes patients – Medical Dialogues
Neuroprotective effects of glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are independent of glycemic control, says an article published in Journal of Diabetes and its Complications. Stroke accounts…